{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:53:23Z","timestamp":1775526803855,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.03.065","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T17:28:42Z","timestamp":1428254922000},"page":"2485-2492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Josefina B.","family":"Cadorna-Carlos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-3863","authenticated-orcid":false,"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charissa Fay","family":"Borja-Tabora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Cecilia","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinandus J.","family":"de Looze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Eizenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanee","family":"Hutagalung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"P\u00e9pin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2015.03.065_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2015.03.065_bib0140","doi-asserted-by":"crossref","first-page":"D45","DOI":"10.1016\/j.vaccine.2010.08.028","article-title":"The need for quadrivalent vaccine against seasonal influenza","volume":"28","author":"Belshe","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.065_bib0145","first-page":"538","article-title":"First quadrivalent flu vaccine approved","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"RR-07","key":"10.1016\/j.vaccine.2015.03.065_bib0150","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.065_bib0155","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2011.12.098","article-title":"Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine","volume":"30","author":"Reed","year":"2012","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2015.03.065_bib0160","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1016\/j.vaccine.2012.10.025","article-title":"The economic value of a quadrivalent versus trivalent influenza vaccine","volume":"30","author":"Lee","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.065_bib0165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2334-13-224","article-title":"Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults","volume":"13","author":"Beran","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.065_bib0170","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0b013e31825687b0","article-title":"Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"50","key":"10.1016\/j.vaccine.2015.03.065_bib0175","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1016\/j.vaccine.2011.09.109","article-title":"A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults","volume":"29","author":"Block","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.065_bib0180","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jit091","article-title":"A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3\u201317 years","volume":"207","author":"Domachowske","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.03.065_bib0185","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults","volume":"31","author":"Greenberg","year":"2013","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2015.03.065_bib0190","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.vaccine.2013.08.069","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults","volume":"31","author":"Pepin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.065_bib0195","series-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"WHO Global Influenza Surveillance Network","year":"2011"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.065_bib0200","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.065_bib0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.065_bib0210","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2015.03.065_bib0215","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0264-410X(94)90241-0","article-title":"Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial","volume":"12","author":"Govaert","year":"1994","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.03.065_bib0220","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.065_bib0225","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.065_bib0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S0950268800030004","article-title":"Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses","volume":"102","author":"Davies","year":"1989","journal-title":"Epidemiol Infect"},{"issue":"20","key":"10.1016\/j.vaccine.2015.03.065_bib0235","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2015.03.065_bib0240","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2015.03.065_bib0245","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","author":"Greenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2015.03.065_bib0250","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.065_bib0255","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3345\/kjp.2012.55.12.474","article-title":"Evaluation of immunogenicity of the 2008\u20132009 seasonal influenza vaccines by microneutralization test","volume":"55","author":"Kim","year":"2012","journal-title":"Korean J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2015.03.065_bib0260","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1750-2659.2012.00350.x","article-title":"An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults","volume":"7","author":"Talaat","year":"2013","journal-title":"Influenza Other Respir Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T13:23:38Z","timestamp":1598880218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15003849"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}